Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Foundation Medicine, Cambridge, MA, USA.
Cancer Biol Ther. 2022 Dec 31;23(1):112-116. doi: 10.1080/15384047.2022.2029128.
Cholangiocarcinoma is a highly morbid gastrointestinal malignancy for which available therapies are limited. Standard of care includes cytotoxic chemotherapies such as gemcitabine, platinum agents, nab-paclitaxel, and fluoropyrimidine analogues. However, tolerability of these regimens varies, and patients who do not tolerate chemotherapy have limited targeted therapies and immunotherapy options. In cholangiocarcinoma, mesenchymal-epithelial transition factor ( amplification may present an additional opportunity for a targeted therapeutic approach, especially considering emerging data in non-small cell lung cancer. In this case, we present a metastatic cholangiocarcinoma patient with high-level gene amplification for whom capmatinib, a tyrosine kinase inhibitor with activity against c-MET, provided a partial response after cessation of chemotherapy.
胆管癌是一种高度恶性的胃肠道恶性肿瘤，目前可用的治疗方法有限。标准治疗包括细胞毒性化疗药物，如吉西他滨、铂类药物、nab-紫杉醇和氟嘧啶类似物。然而，这些方案的耐受性不同，不能耐受化疗的患者靶向治疗和免疫治疗选择有限。在胆管癌中，间质-上皮转化因子（MET）扩增可能为靶向治疗方法提供了另一个机会，特别是考虑到非小细胞肺癌中的新数据。在本例中，我们报告了一名转移性胆管癌患者，其基因扩增水平较高，对 c-MET 有活性的酪氨酸激酶抑制剂卡马替尼在停止化疗后产生了部分缓解。
